Shopping Cart
- Remove All
- Your shopping cart is currently empty
AF3485, a human mPGES-1 inhibitor, exhibits anti-tumor activity both in vitro and in vivo. It achieves this by reducing PGE2 production, inhibiting EGFR signaling, and decreasing the expression of VEGF and FGF-2, which suppresses tumor-associated angiogenesis. When subchronically administered to mice with human A431 xenograft tumors, AF3485 effectively curtails tumor growth.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | AF3485, a human mPGES-1 inhibitor, exhibits anti-tumor activity both in vitro and in vivo. It achieves this by reducing PGE2 production, inhibiting EGFR signaling, and decreasing the expression of VEGF and FGF-2, which suppresses tumor-associated angiogenesis. When subchronically administered to mice with human A431 xenograft tumors, AF3485 effectively curtails tumor growth. |
Molecular Weight | 398.38 |
Formula | C22H17F3N2O2 |
Cas No. | 1195786-61-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.